Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Anixa Biosciences, Inc. stock logo
ANIX
Anixa Biosciences
$2.54
+1.6%
$2.71
$2.07
$4.20
$81.78M0.4389,483 shs23,656 shs
Kyverna Therapeutics, Inc. stock logo
KYTX
Kyverna Therapeutics
$2.55
-1.2%
$2.13
$1.78
$16.64
$110.21M2.17423,263 shs295,718 shs
BetterLife Pharma Inc. stock logo
PVOTF
BetterLife Pharma
$0.00
$0.03
$0.38
$21.70MN/A52,703 shs198,200 shs
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
$1.45
+1.4%
$1.38
$1.02
$9.29
$82.06M1.06403,479 shs369,502 shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Anixa Biosciences, Inc. stock logo
ANIX
Anixa Biosciences
0.00%-4.21%-9.42%-18.03%+3.31%
Kyverna Therapeutics, Inc. stock logo
KYTX
Kyverna Therapeutics
+13.66%+7.95%+22.86%-8.77%-80.15%
BetterLife Pharma Inc. stock logo
PVOTF
BetterLife Pharma
0.00%0.00%0.00%0.00%0.00%
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
+3.62%+18.18%-10.63%-25.13%-83.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Anixa Biosciences, Inc. stock logo
ANIX
Anixa Biosciences
2.1088 of 5 stars
3.63.00.00.02.21.70.0
Kyverna Therapeutics, Inc. stock logo
KYTX
Kyverna Therapeutics
2.1646 of 5 stars
3.63.00.00.02.51.70.0
BetterLife Pharma Inc. stock logo
PVOTF
BetterLife Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
4.0672 of 5 stars
4.54.00.00.03.53.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Anixa Biosciences, Inc. stock logo
ANIX
Anixa Biosciences
3.25
Buy$9.00254.33% Upside
Kyverna Therapeutics, Inc. stock logo
KYTX
Kyverna Therapeutics
3.14
Buy$18.50625.49% Upside
BetterLife Pharma Inc. stock logo
PVOTF
BetterLife Pharma
0.00
N/AN/AN/A
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
3.00
Buy$7.80437.93% Upside

Current Analyst Ratings Breakdown

Latest PVOTF, ANIX, TCRX, and KYTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/27/2025
Kyverna Therapeutics, Inc. stock logo
KYTX
Kyverna Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$4.00 ➝ $5.00
5/7/2025
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$15.00 ➝ $10.00
5/6/2025
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$7.00
4/10/2025
Anixa Biosciences, Inc. stock logo
ANIX
Anixa Biosciences
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
4/8/2025
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
4/3/2025
Kyverna Therapeutics, Inc. stock logo
KYTX
Kyverna Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$6.00 ➝ $4.00
4/1/2025
Kyverna Therapeutics, Inc. stock logo
KYTX
Kyverna Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$40.00 ➝ $20.00
3/26/2025
Anixa Biosciences, Inc. stock logo
ANIX
Anixa Biosciences
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
3/25/2025
Anixa Biosciences, Inc. stock logo
ANIX
Anixa Biosciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
3/21/2025
Anixa Biosciences, Inc. stock logo
ANIX
Anixa Biosciences
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$10.00
3/14/2025
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight$10.00
(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Anixa Biosciences, Inc. stock logo
ANIX
Anixa Biosciences
$210K389.43N/AN/A$0.59 per share4.31
Kyverna Therapeutics, Inc. stock logo
KYTX
Kyverna Therapeutics
$7.03M15.68N/AN/AN/A
BetterLife Pharma Inc. stock logo
PVOTF
BetterLife Pharma
N/AN/AN/AN/A$0.01 per shareN/A
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
$4.42M18.56N/AN/A$3.15 per share0.46
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Anixa Biosciences, Inc. stock logo
ANIX
Anixa Biosciences
-$12.55M-$0.39N/AN/AN/A-58.55%-53.29%6/3/2025 (Estimated)
Kyverna Therapeutics, Inc. stock logo
KYTX
Kyverna Therapeutics
-$60.37M-$3.38N/AN/AN/AN/A-51.12%-37.91%8/11/2025 (Estimated)
BetterLife Pharma Inc. stock logo
PVOTF
BetterLife Pharma
-$14.78MN/AN/AN/AN/AN/A-205.15%-147.23%N/A
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
-$89.22M-$1.09N/AN/AN/A-1,188.88%-58.72%-36.02%8/11/2025 (Estimated)

Latest PVOTF, ANIX, TCRX, and KYTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/3/2025Q2 2025
Anixa Biosciences, Inc. stock logo
ANIX
Anixa Biosciences
-$0.10-$0.09+$0.01-$0.09N/AN/A
5/13/2025Q1 2025
Kyverna Therapeutics, Inc. stock logo
KYTX
Kyverna Therapeutics
-$1.21-$1.03+$0.18-$1.03N/AN/A
5/12/2025Q1 2025
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
-$0.28-$0.26+$0.02-$0.26$1.62 million$2.17 million
3/27/2025Q4 2024
Kyverna Therapeutics, Inc. stock logo
KYTX
Kyverna Therapeutics
-$0.87-$0.88-$0.01-$0.88N/AN/A
3/11/2025Q1 2025
Anixa Biosciences, Inc. stock logo
ANIX
Anixa Biosciences
-$0.10-$0.10N/A-$0.10N/AN/A
3/5/2025Q4 2024
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
-$0.27-$0.29-$0.02-$0.30$1.43 million$0.67 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Anixa Biosciences, Inc. stock logo
ANIX
Anixa Biosciences
N/AN/AN/AN/AN/A
Kyverna Therapeutics, Inc. stock logo
KYTX
Kyverna Therapeutics
N/AN/AN/AN/AN/A
BetterLife Pharma Inc. stock logo
PVOTF
BetterLife Pharma
N/AN/AN/AN/AN/A
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Anixa Biosciences, Inc. stock logo
ANIX
Anixa Biosciences
N/A
8.54
8.54
Kyverna Therapeutics, Inc. stock logo
KYTX
Kyverna Therapeutics
N/A
10.50
10.50
BetterLife Pharma Inc. stock logo
PVOTF
BetterLife Pharma
N/A
3.62
3.62
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
0.13
9.56
9.56

Institutional Ownership

CompanyInstitutional Ownership
Anixa Biosciences, Inc. stock logo
ANIX
Anixa Biosciences
29.13%
Kyverna Therapeutics, Inc. stock logo
KYTX
Kyverna Therapeutics
18.08%
BetterLife Pharma Inc. stock logo
PVOTF
BetterLife Pharma
N/A
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
82.83%

Insider Ownership

CompanyInsider Ownership
Anixa Biosciences, Inc. stock logo
ANIX
Anixa Biosciences
25.30%
Kyverna Therapeutics, Inc. stock logo
KYTX
Kyverna Therapeutics
22.00%
BetterLife Pharma Inc. stock logo
PVOTF
BetterLife Pharma
34.77%
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
4.35%
CompanyEmployeesShares OutstandingFree FloatOptionable
Anixa Biosciences, Inc. stock logo
ANIX
Anixa Biosciences
532.20 million24.05 millionOptionable
Kyverna Therapeutics, Inc. stock logo
KYTX
Kyverna Therapeutics
9643.22 millionN/AOptionable
BetterLife Pharma Inc. stock logo
PVOTF
BetterLife Pharma
N/A171.41 millionN/ANot Optionable
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
10056.59 million51.90 millionNot Optionable

Recent News About These Companies

Needham Sticks to Its Buy Rating for TScan Therapeutics (TCRX)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Anixa Biosciences stock logo

Anixa Biosciences NASDAQ:ANIX

$2.54 +0.04 (+1.60%)
Closing price 04:00 PM Eastern
Extended Trading
$2.54 +0.00 (+0.20%)
As of 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Kyverna Therapeutics stock logo

Kyverna Therapeutics NASDAQ:KYTX

$2.55 -0.03 (-1.16%)
Closing price 04:00 PM Eastern
Extended Trading
$2.56 +0.01 (+0.20%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

BetterLife Pharma stock logo

BetterLife Pharma OTCMKTS:PVOTF

BetterLife Pharma, Inc. is an early stage pharmaceutical company, which engages in the development and commercialization of therapeutic pharmaceutical and nutraceutical products. It also offers drug delivery platform technologies. Its product lines include capsules, tablets, and softgels; bulk powder; stick packs; beverages; oral solutions; lotions, creams, and gels; pet food additives; gum, mints, and candies; and sexual health products. It distributes its product under the Pivot Naturals brand. The company was founded on June 10, 2002 and is headquartered in Vancouver, Canada.

TScan Therapeutics stock logo

TScan Therapeutics NASDAQ:TCRX

$1.45 +0.02 (+1.40%)
Closing price 04:00 PM Eastern
Extended Trading
$1.43 -0.02 (-1.38%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.